NEW YORK (GenomeWeb News) – Cancer diagnostics services firm BioTheranostics today announced a contract with preferred provider organization Three Rivers Provider Network.
The contract covers the San Diego firm's testing services, including CancerType ID for diagnosing metastatic cancer, and Breast Cancer Index for predicting the risks of recurrence of early stage, estrogen receptor-positive breast cancer. The agreement makes BioTheranostics' tests available to an additional 15 million covered lives in the US, the firm said.
BioTheranostics CEO Richard Ding said that the deal with Three Rivers brings the total number of covered lives in the US under contract for CancerType ID to 91 million.
The company said in August that it received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID.